Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

754 participants

Study Classification

OBSERVATIONAL

Study Start Date

1991-10-31

Study Completion Date

2009-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if tumor cells can be detected in the peripheral blood and/or bone marrow of patients with melanoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Detection of Circulating Osteosarcoma Tumor Cells in the Blood of Patients Using the Polymerase Chain Reaction

NCT00588510

Osteosarcoma

COMPLETED

Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy

NCT00897481

Melanoma (Skin)

UNKNOWN

Bone Marrow and Blood Samples From Patients With Metastatic Choroid Melanoma

NCT00897624

Intraocular Melanoma

COMPLETED

Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma

NCT00004153

Melanoma (Skin)

COMPLETED NA

Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer.

NCT00974610

Breast Cancer Colorectal Cancer Lung Cancer +2 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with melanoma can succumb to subclinical metastatic disease, not detectable at presentation by conventional physical examination, hematologic and biochemical screening, or radiologic evaluation. More intensive radiologic evaluation with CT or radioisotope scanning has not proven to be useful. What may be useful is a more sensitive method of staging melanoma patients at presentation, specifically evaluating them for subclinical systemic disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Melanoma patients

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

MSK Patients with histologically confirmed melanoma of any site and at least one of the following:

* Primary tumor \> 4.0 mm thick (AJCC Stage IIB)
* Clinically or histologically positive regional nodes (AJCC Stage III)
* Any in transit disease (AJCC Stage III)
* Any systemic metastases (AJCC Stage IV)

Eligible Sex

ALL

Accepts Healthy Volunteers

No